Search Videos and More
News
Dana-Farber researchers to present findings at 2025 San Antonio Breast Cancer Symposium
Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
Document
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held meetings to discuss recommendations regarding the use of inavolisib, palbociclib, and fulvestrant in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
Dana-Farber Research News 12.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.
Symposium
San Antonio Breast Cancer Symposium 2025
Many Dana-Farber clinician scientists are participating in the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12 in San Antonio Texas.
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.
Video
ESMO25 Breast Cancer Highlights: monarchE and NATALEE
Harold Burstein, MD, PhD, and Sarah Sammons, MD, discuss the monarchE and NATALEE trials, investigating CDK4/6 inhibitors for high-risk, early stage, HR+ breast cancer.
Video
ESMO25 Breast Cancer Highlights: evERA and SERENA6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective estrogen receptor degraders (SERDs).
Video
ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
Video
ESMO25 Breast Cancer Highlight Recap
Harold Burstein, MD, PhD, summarizes important breakthroughs presented at ESMO 2025 for all sub-types and stages of breast cancer.
Video
ESMO25 Breast Cancer Highlights
Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ESMO 2025.
Video
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025